scholarly journals Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma

2018 ◽  
Vol 32 (5) ◽  
pp. 348-362 ◽  
Author(s):  
Hiroaki Ishiguchi ◽  
Shinji Ito ◽  
Katsuhiko Kato ◽  
Yusuke Sakurai ◽  
Hisashi Kawai ◽  
...  
Keyword(s):  
Lymph Node ◽  
Bone Metastases ◽  
Fdg Pet ◽  
Diffusion Weighted Imaging ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Diffusion Weighted ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI

2014 ◽  
Vol 53 (03) ◽  
pp. 89-94 ◽  
Author(s):  
D. H. Lee ◽  
J.-K Yoon ◽  
S. J. Lee ◽  
T. H. Kim ◽  
D. K. Kang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Diagnostic Performance ◽  
Axillary Lymph ◽  
Diagnostic Ability ◽  
Node Metastasis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

SummaryThe aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients. Patients, methods: Pre- operative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT). Results: In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultraso- nography+MRI, p = 0.05). Conclusion: The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB

2021 ◽  
Author(s):  
E.H.A. Stahlie ◽  
B. van der Hiel ◽  
A. Bruining ◽  
B. van de Wiel ◽  
Y.M. Schrage ◽  
...  
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Whole Body ◽  
Pet Ct ◽  
Melanoma Patients ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Lymph Node Ultrasound

Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study

2018 ◽  
Vol 36 (6) ◽  
pp. 382-393 ◽  
Author(s):  
Mohammad Abd Alkhalik Basha ◽  
Maged Abdel Gelil Hamed ◽  
Rania Refaat ◽  
Mohamad Zakarya AlAzzazy ◽  
Manar A. Bessar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Comparative Study ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Whole Body Mri ◽  
Pet Ct ◽  
Prospective Comparative Study ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Detection of Ureteral Stump Transitional Cell Carcinoma, Presenting as Bone Metastases from Unknown Primary by 18F-FDG PET/CT: A Case Report with Review of Literature

2022 ◽  
Author(s):  
Petya N. Nikolova ◽  
Valeria H. Hadzhiyska ◽  
Kiril B. Mladenov ◽  
Mihaela G. Ilcheva ◽  
Stefani Veneva ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Bone Metastases ◽  
Fdg Pet ◽  
Transitional Cell ◽  
Pain Syndrome ◽  
Whole Body ◽  
Unknown Primary ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

AbstractA case of occult carcinoma of the ureteral stump is reported. A 67-year-old man presented with pain syndrome due to multiple bone metastases from unknown primary origin detected by previous imaging studies as magnetic resonance imaging, whole body contrast-enhanced computed tomography (CT), and technetium-99m methyldiphosphonate bone scan. He had undergone a right nephrectomy for a benign disease previously. He was referred to our department for an 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) to help localize possible primary tumor. Our observations in this case show that the use of 18F-FDG PET/CT successfully and more accurately evaluated the overall tumor burden and led to a rapid decision of an adequate therapeutic approach.

Diagnostic Performance of 18F-FDG PET/CT for Lymph Node Staging in Patients with Operable Non-small-cell Lung Cancer and Inflammatory Lung Disease

Lung ◽  
2008 ◽  
Vol 186 (5) ◽  
pp. 327-336 ◽  
Author(s):  
Young-Sil An ◽  
Joo Sung Sun ◽  
Kyung Joo Park ◽  
Sung Chul Hwang ◽  
Kwang Joo Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Small Cell ◽  
Lymph Node Staging ◽  
Small Cell Lung ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Newly Diagnosed Lymphoma: Initial Results With Whole-Body T1-Weighted, STIR, and Diffusion-Weighted MRI Compared With 18F-FDG PET/CT

2011 ◽  
Vol 196 (3) ◽  
pp. 662-669 ◽  
Author(s):  
Henriëtte M. E. Quarles van Ufford ◽  
Thomas C. Kwee ◽  
Frederik J. Beek ◽  
Maarten S. van Leeuwen ◽  
Taro Takahara ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Diffusion Weighted Mri ◽  
Diffusion Weighted ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
And Diffusion ◽  
Initial Results

scholarly journals Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Gil-Sun Hong ◽  
Eun Jin Chae ◽  
Jin-Sook Ryu ◽  
Sun Young Chae ◽  
Hyo Sang Lee ◽  
...  
Keyword(s):  
Prospective Study ◽  
Fdg Pet ◽  
Diffusion Weighted Imaging ◽  
High Specificity ◽  
Whole Body ◽  
Indolent Lymphoma ◽  
Body Regions ◽  
Diffusion Weighted ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background We prospectively evaluated the diagnostic utility of whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery MRI (WB-DWIBS/STIR) for the pretherapeutic staging of indolent lymphoma in 30 patients. Methods This prospective study included 30 treatment-naive patients with indolent lymphomas who underwent WB-DWIBS/STIR and conventional imaging workup plus biopsy. The pretherapeutic staging agreement, sensitivity, and specificity of WB-DWIBS/STIR were investigated with reference to the multimodality and multidisciplinary consensus review for nodal and extranodal lesions excluding bone marrow. Results In the pretherapeutic staging, WB-DWIBS/STIR showed very good agreement (κ = 0.96; confidence interval [CI], 0.88–1.00), high sensitivity (93.4–95.1%), and high specificity (99.0–99.4%) for the whole-body regions. These results were similar to those of 18F-FDG-PET/CT, except for the sensitivity for extranodal lesions. For extranodal lesions, WB-DWIBS/STIR showed higher sensitivity compared to 18F-FDG-PET/CT for the whole-body regions (94.9–96.8% vs. 79.6–86.3%, P = 0.058). Conclusion WB-DWIBS/STIR is an effective modality for the pretherapeutic staging of indolent lymphoma, and it has benefits when evaluating extranodal lesions, compared with 18F-FDG-PET/CT.

Sign in / Sign up

Export Citation Format

Share Document